Loading
Neurological Disorders and Treatments / Metabolism and Genetic Disorders · Journal article
Current Opinion in Clinical Nutrition & Metabolic Care · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review presents emerging evidence that adequate choline intake may influence metabolic health outcomes including obesity, liver disease, and type 2 diabetes, while reframing circulating TMAO as a marker of metabolic dysfunction rather than a direct dietary choline effect. The evidence is largely observational and preclinical; the review identifies mechanistic understanding and study methodology as critical gaps and calls for investigation of choline requirements in the context of new antiobesity medications.
Narrative review. Clinical and preclinical studies on metabolic disease populations; no specific enrolled population reported in this review..
Low choline intake has been linked to obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes, and obesity-associated cognitive decline Circulating trimethylamine N-oxide (TMAO) is reframed as a marker of metabolic dysfunction driven by obesity and high-fat diet rather than a direct consequence of dietary choline intake Preclinical and clinical studies suggest adequate choline intake may be protective against obesity-related disease progression, particularly when established early in life
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that choline may be an important nutritional factor in metabolic disease management, but current evidence does not yet support routine choline supplementation as a standard intervention. Further investigation of choline requirements in the context of weight loss medications is warranted.
A narrative review synthesizing recent evidence on choline's role in metabolic health, identifying research gaps and future directions rather than reporting new primary data or definitive findings.
As stated by the source record.
Clinicians should be aware that choline may be an important nutritional factor in metabolic disease management, but current evidence does not yet support routine choline supplementation as a standard intervention. Further investigation of choline requirements in the context of weight loss medications is warranted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
PURPOSE OF REVIEW: Emerging evidence suggests that choline plays a significant role in mediating metabolic disease beyond the regulation of hepatic triglycerides. The aim of this article is to present a current, brief synthesis focused on the impact of choline intake on metabolic health and to identify future directions in this research space. RECENT FINDINGS: Recent work has linked low choline intake to obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes, and obesity-associated cognitive decline. A new methodology now enables more precise discrimination of choline intake in clinical populations. Emerging evidence reframes circulating trimethylamine N-oxide (TMAO) as a marker of metabolic dysfunction driven by obesity and a high-fat diet, rather than a direct consequence of dietary choline intake. Preclinical and clinical studies further suggest that adequate choline intake may be protective against obesity-related disease progression, particularly when established early in life. SUMMARY: Choline is emerging as an important mediator of metabolic health and disease progression. A deeper understanding of the mechanisms regulating choline metabolism is critical to tailor nutritional therapies and mitigate metabolic disease progression. The impact of new antiobesity medications, including GLP-1 receptor agonists, on choline requirements also warrants investigation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.